Nanobiotix shares give ground but remain up 37% over one month
The Paris-based oncology nanomedicine biotech is losing ground at midday, in an almost stable Paris market. This modest decline follows a sharp recovery over the past few weeks, while management prepares two meetings with the financial community in London.
A 1.31% decline that does not dent the November rebound
Nanobiotix is down 1.31% at €28.66 intraday, but the stock still shows a 36.87% gain over one month, after hitting a low point in October. This decline is among the steepest in the SBF 120, while the index is stable.
The share price remains above its MM20 at €26.97 (a gap of 6.27%) and its MM50 at €26.74 (a gap of 7.18%). However, it stays below its MM200 at €29.75, a gap of 3.66%, a level the stock had sought to reach in recent days.
Over three months, the stock is still down 16.98%, a reminder of the scale of the back-to-school sell-off that the rebound has only partly erased.
Jefferies and UBS conferences in London, the stock's next scheduled event
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In the wake of this move, the company announced that it would present its work at the conferences organized by Jefferies and UBS in London on November 16 and 17. These appearances before the financial community are scheduled on this month's calendar.
On the balance sheet side, the first-half 2026 results, published on September 24, show cash of €110.9 million, which the company considers sufficient to fund its operations until 2029. The stock, listed in Paris and as ADSs on Nasdaq, trades close to its MM200, a level it had approached in recent days.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
